2020 CINP World Congress - First Announcement & Call for Abstracts - 25-28 June 2020 Taipei, Taiwan
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2020 CINP
World Congress
25-28 June 2020 Taipei, Taiwan
First Announcement
& Call for Abstracts
cinp2020.org | cinp2020@cinp.org
Welcome Message
On behalf of the Executive Committee exciting time for the understanding of
of the International College of psychiatric pathophysiology and the
Neuropsychopharmacology (CINP), it 32nd World Congress will feature the
is my pleasure to invite you to the 32nd most up-to-date research, diverse
CINP World Congress of topics of interest, and educational
Neuropharmacology in Taipei, Taiwan sessions with leading experts.
in June 2020. This upcoming World
Congress welcomes delegates from all We hope that you will be able to join us
over the globe to the beautiful city of to advance the research and education
Taipei to carry on the momentum of of psychopharmacology.
the previous World Congresses in Seoul
and Vienna. Building on our previous
efforts, we will expand our core mission
of linking the advances in brain
sciences to the alleviation of the Professor
distress and disabilities associated with Siegfried Kasper
neuropsychiatric disorders. With President of CINP
advances in neuroscience, this is an (2018 – 2020)
02 2020 CINP World Congress
Taipei International Convention Center
Important Dates
15 November 2019
Registrations open
15 November 2019
Abstract submissions open
30 January 2020
Abstract submissions close
Visit www.cinp2020.org
to submit your abstract and register!
cinp2020.org | cinp2020@cinp.org 03
About CINP
The International College of Neuropsychophar-
macology (CINP) is a truly worldwide organiza-
tion established over 50 years ago in Zurich,
Switzerland. CINP hold meetings all over the
world with the aim to promote research and
education on a worldwide basis. With the change
to go annual with the CINP World Congress, the
college will also focus more on smaller seminars
and workshops in between.
The Executive Committee and Councilors of
CINP are nominated by the membership and
serve as an officer of the College for a minimum
of 4 years. These individuals cover a wide range
of disciplines within the field, from psychiatrists,
psychopharmacologists, basic and clinical
researchers to clinical psychologists. CINP also
relies on its many subcommittees who undertake
a variety of activities for the College.
Membership of the College is available to any
individual to apply for and we offer members the
opportunity to become part of this knowledge-
able group of scientists who work at an
international level. The membership application
is reviewed by a dedicated committee on a
regular basis and applications can be made
online. As a member of CINP you may have the
opportunity to be invited to one of the smaller
meetings or invited to participate in the running
of the College by sitting on a subcommittee.
Oxford University Press has a rich history dating
back to 1478; today OUP has 6,000 employees in
offices in 50 countries and is the largest university
press in the world. OUP has an incredibly diverse
publishing program; publishing in more than 40
languages and in a variety of formats–print and
digital, for all audiences–from pre-school to
secondary level schoolchildren; students to
academics; general readers to researchers and
clinicians; individuals to institutions. As a
department of the University of Oxford, our
worldwide publishing furthers the University's
objectives of excellence in scholarship, research,
and education.
For more information about
the College visit www.cinp.org
04 2020 CINP World Congress
CINP 2020 Committees
Executive Committee International Scientific Programme
CINP President Committee
Siegfried Kasper, Austria Chair
CINP Past President Pierre Blier, Canada
John H. Krystal, USA Co-chair
CINP President Elect Elias Eriksson, Sweden
Pierre Blier, Canada Co-chair
CINP Vice President Noriko Osumi, Japan
Shih-Ku Lin, Taiwan
CINP Vice President Chiou, Lih-Chu, Taiwan
Joseph Zohar, Israel Cryan, John, Ireland
CINP Secretary Domschke, Katharina, Germany
Elias Eriksson, Sweden Falkai, Peter, Germany
Fountoulakis, Kostas, Greece
CINP Treasurer
Frazer, Alan, USA
Kazutaka Ikeda, Japan
Gobbi, Gabriella, Canada
Huang, Ming-Chyi, Taiwan
Councillors Hiroi, Noboru, USA
Helena Calil, Brazil Ikeda, Kazutaka, Japan
Ryota Hashimoto, Japan Kasper, Siegfried, Austria
Katharina Domschke, Germany Kwon, Jun Soo, Korea
Jun Soo Kwon, Republic of Korea Krystal, John, USA
Atsumi Nitta, Japan Lanzenberger, Rupert, Austria
Lin, Shih-Ku, Taiwan
Peter Falkai, Germany
McGuire, Philip, UK
Maurizio Fava, USA Morilak, David, USA
Carol Tamminga, USA Shamay-Tsoory, Simone, Israel
Allan Young, United Kingdom Soldatos, Constantin, Greece
Gabriella Gobbi, Canada Tamminga, Carol, USA
Uchida, Hiroyuki, Japan
Yamawaki, Shigeto, Japan
Zohar, Joseph, Israel
cinp2020.org | cinp2020@cinp.org 05
CINP 2020 Committees
Local Organizing Committee South Asia & South-East Asia Committee
Co-chair (SASEAC)
Shih-Ku Lin, Taiwan Co-chair
Co-chair Yen-Kuang Yang, Taiwan
Yen-Kuang Yang, Taiwan Co-chair
Co-chair Po-See Chen, Taiwan
Po-See Chen, Taiwan
Andi Jayalangkara Tanra, Indonesia
Bai, Ya-Mei, Taiwan Azimatul Karimah, Indonesia
Chen, Cheng-Sheng, Taiwan Dang Duy Thanh, Vietnam
Chen, Chia-Hsiang, Taiwan Kim Savuon, Cambodia
Chen, Chih-Cheng, Taiwan Kristian Liaury, Indonesia
Chen, Chih-Ken, Taiwan Kua Ee Heok, Singapore
Chiou, Lih-Chu, Taiwan Ng Chong Guan, Malaysia
Chong, Mian-Yoon, Taiwan Samai Sirithongthaworm, Thailand
Gau, Shur-Fen, Taiwan Tjhin Wiguna, Indonesia
Gean, Po-Wu, Taiwan Tu Trung Lam, Vietnam
Huang, Ming-Chyi, Taiwan
Huang, San-Yuan, Taiwan AsCNP Committee
Huang, Tiao-Lai, Taiwan Chair
Hwang, Tzung-Jeng, Taiwan Kazutaka Ikeda, AsCNP President, Japan
Ko, Chih-Hung, Taiwan Co-chair
Lane, Hsien-Yuan, Taiwan Chay Hoon Tan, AsCNP President-Elect,
Lee, Chau-Shoun, Taiwan Singapore
Liu, Chia-Yih, Taiwan Co-chair
Andi J. Tanra, AsCNP Past President,
Liu, Yu-Li, Taiwan Indonesia
Shen, Winston W., Taiwan
Su, Kuan-Pin, Ta Atsumi Nitta, Japan
Su, Tung-Ping, Taiwan Chan Hyung Kim, Korea
Sangyeol Lee, Korea
Shigeto Yamawaki, Japan
Shih-Ku Lin, Taiwan
Suresh Sundram, Australia
Tianmei Si, China
Young Chul Chung, Korea
06 2020 CINP World Congress
Call for Abstracts
The CINP Executive Committee Abstract submissions should
welcomes the submission of abstracts preferably be structured as follows:
for poster presentations. • Background
• Aims & Objectives
A small number of the abstracts intended
for posters will be selected to be presented • Methods
as 15+3 min oral presentations in a • Results
symposium on the topic in question. • Discussion & Conclusion
Please indicate on the submission form if
• References – use Harvard style, where
you want your abstract to be considered
each reference is numbered in order of use
for an oral presentation.
Important Deadlines
If you are 35 years old or younger, please
consider applying for the Rafaelsen Young Abstract submission
Investigators Travel Award. Visit Deadline: 30 January 2020
www.cinp2020.org for more details.
Notification of Acceptance/Rejection:
Submission Guidelines 2 March 2020
• Abstracts must be in English
Change of Title/Authorship:
• The abstract must not exceed 500 words
Deadline: 16 March 2020
• A table or figure will count as 150 words
• The total word count does not include Presenting Author Registration
the title, authors' details or references Deadline: 16 March 2020
• The name of the presenting author
should appear first in the list of authors
• CINP recommends using the NbN Submit your abstract now!
nomenclature for psychotropics www.cinp2020.org/abstract-submissions
(nbn2r.com)
cinp2020.org | cinp2020@cinp.org 07
Programme at a Glance
Thursday, 25 June 2020
ROOM 201 ROOM 201 ROOM 201 ROOM 201 ROOM 201
PLENARY HALL
A B C D E
Pre-Congress Pre-Congress Pre-Congress Early career Pre-Congress
workshop on workshop on workshop on researchers’ workshop on
14:00 managing on challenging rational and research in Asian
- workshop: Clinical ROOM 102
treatment resistant cases of OCD: from irrational research in Psychotropic Drug
17:30 depression in 2020 diagnosis to polypharmacy progress on Prescription
Diane McIntosh, treatment Pierre Blier, addictive medicine (REAP): Past,
Canada Joseph Zohar, Israel Canada present and future
18:30
- Opening and
Awards Ceremony
19:45
19:45
- Networking
Welcome
Break
Reception
21:00
LEGEND
Plenary Lecture Symposium Debate Regional Symposium Pre-Congress Workshop
Clinical Focus and Frontiers The Selected One Session in Chinese Other
Download the
CINP Mobile App
How to download
Scan one of these barcodes.
Search ‘CINP ’ in the Apple
App or Google Play Store. http://bit.ly/2DzW4RL http://bit.ly/2Dxmtj0
08 2020 CINP World Congress
Programme at a Glance
Friday, 26 June 2020
ROOM 201 ROOM 201 ROOM 101 ROOM 101
PLENARY HALL ROOM 102 ROOM 105
A+ B+C D+E+F A+B C+D
Plenary Lecture:
From genes to clinical
08:45 phenotype in ADHD
- across the lifespan
09:30 - Barbara Franke,
Radboud University,
The Netherlands
09:30
- Networking
Networking
Break Break
10:00
Symposium 1: Next generation
Gene-environment Symposium 3: Novel
Symposium 2: brain imaging The selected The selected seizure therapy
10:00 interaction in
strategies to assess
- schizophrenia: Genetic Treatment Regional ones (Oral ones (Oral and
pathophysiology and
load modulates the Resistant treatment effects in Symposium Abstracts) Abstracts) neuromodulation
11:30 deleterious impact of Depression (TRD) neuropsychiatric (Theme A) (Theme B)
stressors to lead to the (in Chinese)
emergence of psychosis disorders
Lunch
Satellite Symposia
11:30
Plenary Educational Workshops (PEW)
-
Meet with... John (Krystal): Psychosis*
13:00
Meet with... Katharina (Domschke): Anxiety*
*Pre-registration required; preference given to CINP members
Symposium 5: Symposium 6:
Non-substance
Symposium 4: Partial dopamine Ethical Challenges
addictive
13:00 agonists: Wide Clinical
Substance abuse of Genomic In the Behaviour focus and
disorders
- and psychosis: New spectrum addiction (behavioral
Research in pipeline frontiers
14:30 insights on old medications for Neuropsychiatric session addiction)
psychiatric (OCD)
problems Disorders
disorders (in Chinese)
Symposium 7: The Symposium 8:
Interplay of stress
Altered Circadian Symposium 9: Debate Pharmacokinetic
cascade and NMDAR Opioid Clinical
14:45 dysfunction in the Rhythms in Editors' Top Cannabinoids and
- Psychiatric Mood Pharmacology Gabriella focus and
pathogenesis of mental Publications frontiers
pharmacogenetics
disorders: identifying Disorders: New Updates: toward - session 1 Gobbi vs.
16:15 novel antioxidants and precision (ADHD)
Treatment David Nutt (in Chinese)
NMDAR modulators for
Strategies pharmacotherapy
treatment and diagnosis
16:15
- Networking Break
16:45
Plenary Lecture:
What is life:
16:45 implications for
- brain health - Josef
17:30 Penninger, Life
Sciences Institute,
UBC, Canada
18:00
- Top 10 posters - guided session
19:30
LEGEND
Plenary Lecture Symposium Debate Regional Symposium Pre-Congress Workshop
Clinical Focus and Frontiers The Selected One Session in Chinese Other
cinp2020.org | cinp2020@cinp.org 09
Programme at a Glance
Saturday 27 June 2020
ROOM 201 ROOM 201 ROOM 101 ROOM 101
PLENARY HALL ROOM 102 ROOM 105
A+ B+C D+E+F A+B C+D
Plenary Lecture:
08:45 Big data analyses for
neuropsychopharmacology
-
- Tung-Ping Su,
09:30 Cheng-Hsin General
Hospital, Taiwan
09:30
- Networking
Networking
Break Break
10:00
Symposium 11: Symposium 12: The selected Pharmacoepide-
10:00 Symposium 10: Novel mechanisms Mechanisms of
- Regional ones (Oral miology
Risk and Resilience of action of stress in Symposium Abstracts)
11:30 in Addiction antidepressant pathophysiology of (Theme C) (in Chinese)
treatment brain illness
Lunch
Satellite Symposia
11:30
Plenary Educational Workshops (PEW)
-
Meet with... Naomi (Fineberg): OCD*
13:00
Meet with... Pierre (Blier): TRD*
*Pre-registration required; preference given to CINP members
Symposium 14: Symposium 15:
Symposium 13: Impulsive-compul- Epigenetics in Aging,
13:00 sive disorders: Anxiety- and The selected Clinical Stem Cell
Molecular imaging Rafaelsen ones (Oral focus and Therapy: State of
- in drug where neurobiology Stress-Related Symposium Abstracts) frontiers the art
14:30 development: Is meets Disorders – Progress,
evidence-based Perspectives and (Theme D) (Depression) (in Chinese)
there any progress?
treatment Pitfalls
Symposium 16: The
Importance of the Symposium 17: Rapid Symposium 18: Clinical
Debate focus and Ketamine: The
14:45 Muscarinic M1 onset and sustained Synaptopathy Editors' Top Pharmacogenetics
- Receptor in CNS action of ketamine in
mechanisms in Publications Alessandro Serretti frontiers good and the bad
Function and as a Drug depressive episodes:
psychiatric - session 2 vs. Henk-Jan (Difficult to
16:15 Target for Cognitive from the laboratory to Guchelaar treat (in Chinese)
Deficits and Sleep in the community disorders
Schizophrenia psychosis)
16:15
- Networking Break
16:45
Plenary Lecture:
Brain mechanisms of
16:45 insomnia: fMRI and
- GWAS perspectives on
causes and consequences
17:30 - Eus Van Someren, Vrije
Universiteit Amsterdam,
The Netherlands
LEGEND
Plenary Lecture Symposium Debate Regional Symposium Pre-Congress Workshop
Clinical Focus and Frontiers The Selected One Session in Chinese Other
10 2020 CINP World CongressProgramme at a Glance
Sunday 28 June 2020
ROOM 201 ROOM 201 ROOM 101 ROOM 101
PLENARY HALL ROOM 102
A+ B+C D+E+F A+B C+D
Plenary Lecture:
Transgenerational
08:45 epigenetics: A key to
- understand
neurodevelopmental
09:30 diseases
- Noriko Osumi, Tohoku
University, Japan
09:30
- Networking
Networking
Break Break
10:00
Symposium 20:
Epigenomic Symposium 21:
pathophysiology of Stronger together? The selected Clinical
10:00 Symposium 19: Bipolar Disorder:
- Using PET and Regional ones (Oral focus and
Estrogen and Human tissue
Symposium
investigations of MRI in Abstracts) frontiers
11:30 psychiatric illnesses
mechanisms, neuropsychophar- (Theme E) (Insomnia)
biomarkers, and macology
single-cell pathology
Lunch
Satellite Symposia
11:30
Plenary Educational Workshops (PEW)
-
Meet with... Gabriella (Gobbi): Cannabis*
13:00
Meet with... Elias (Eriksson): Antidepressants*
*Pre-registration required; preference given to CINP members
Debate
Symposium 22: Symposium 24: Novel
Transgender Symposium 23: Molecular and Cellular Is long-term treatment
The selected
13:00 Mechanisms of Mechanisms of with antipsychotics
- hormone therapy: ones (Oral
effects on brain stress response at Rapid-acting justified?
Abstracts)
14:30 the single cell Antidepressant Konstantinos
structure and Ketamine and Its (Theme F)
function resolution Enantiomers
Fountoulakis vs.
Robin Murray
Plenary Lecture:
Effects of cannabis in
14:45 adolescence and
- depression risk in young
adulthood: From animals
15:30 to human studies
- Gabriella Gobbi,
McGill University, Canada
15:45
- Closing Ceremony
16:15
LEGEND
Plenary Lecture Symposium Debate Regional Symposium Pre-Congress Workshop
Clinical Focus and Frontiers The Selected One Session in Chinese Other
cinp2020.org | cinp2020@cinp.org 11Preliminary Programme Friday, 26 June 2020
08.45 - 09.30 | Plenary Hall 10:00 – 11.30 | Room 201 A+B+C
PLENARY LECTURE SYMPOSIUM 2
From genes to clinical phenotype Chair: Siegfried Kasper, Austria
in ADHD across the lifespan Treatment Resistant
Barbara Franke, Radboud University, The Depression (TRD)
Netherlands
1. Characterization of treatment resistant
depression in Europe
Siegfried Kasper, Austria
09.30 - 10:00
2. Genetic findings in TRD
Networking Break Chiara Fabbri, Italy
3. Glutamateric approach in TRD
10:00 – 11.30 | Plenary Hall Carlos Zarate, USA
SYMPOSIUM 1 4. Deep brain stimulation in TRD
Chair: Anthony Grace, USA Thomas Schläpfer, Germany
Gene-environment interaction
in schizophrenia: Genetic load 10:00 – 11.30 | Room 201 D+E+F
modulates the deleterious SYMPOSIUM 3
impact of stressors to lead to Chair: Hiroyuki Uchida, Japan
the emergence of psychosis Novel brain imaging strategies
1. Cannabis-associated psychosis; mechanisms to assess pathophysiology and
and implications
Robin Murray, UK
treatment effects in
neuropsychiatric disorders
2. The neuroimmune hypothesis of
schizophrenia and cannabis use relevance in 1. A novel PET tracer for AMPA receptors
youth - novel studies characterizes neuropsychiatric disorders in
with TSPO PET human
Romina Mizrahi, Canada Takuya Takahashi, Japan
3. Inability to regulate stress prepubertally as a 2. First PET imaging of AMPA receptors in
risk factor for schizphrenia: disregulation of schizophrenia and depression
prefrontal-amygdala-hippocampal circuitry Hiroyuki Uchida, Japan
Anthony Grace, USA 3. Antipsychotic effect on glutamate and
4. A convergent circuit for genetic and dopamine system in first-episode psychosis
environmental risk for schizophrenia Euitae Kim, Republic of Korea
Andreas Meyer-Lindenberg, Germany 4. How childhood trauma induces changes in
dopaminergic function to give rise to
psychopathology
Michael Bloomfield, UK
12 2020 CINP World CongressPreliminary Programme Friday, 26 June 2020
11.30 – 13.00 3. The role of brexpiprazole in the treatment of
inadequate response in major depressive disorder
Lunch Diane McIntosh, Canada
Satellite Symposia 4. Long-term use of cariprazine in bipolar disorder
Plenary Educational Workshop Terence Ketter, USA
Meet with...
John Krystal: Psychosis* 13.00 – 14.30 | Room 201 D+E+F
Katharina Domschke: Anxiety*
*Attendance limited. Pre-registration required; SYMPOSIUM 6
preference given to CINP members Chair: Paul Appelbaum, USA
Ethical Challenges of Genomic
13.00 – 14.30 | Plenary Hall Research in Neuropsychiatric
SYMPOSIUM 4
Disorders
Chair: Ke Xu, USA 1. Returning Results in Psychiatric Genomic
Research: Ethical Conundra
Substance abuse and psychosis: Gabriel Lazaro-Munoz, USA
New insights on old problems 2. Informed Consent to Psychiatric Genomic
1. The complex relationships between Research
cannabinoids and psychosis Paul Appelbaum, USA
Deepak Cryil D’Souza, USA
3. NeuroGene, Neuropsychiatric Gen-Ethics,
2. Psychotic and cognitive profiles among and the Dilemma of Facial Phenotyping
chronic ketamine abusers with KAP Ilina Singh, UK
Ni Fan, China 4. Developing Responsible Governance for
3. Genetic and epigenetic vulnerability of Genomic Research in Neuroscience
health cannabis users and the dynamic arena of Adrian Thorogood, Canad
medical cannabis
Celia Morgan, UK
13:00 - 14:30 | Room 102
4. Shared vulnerability and neural pathways
between ketamine-associated psychosis and CLINICAL FOCUS AND FRONTIERS
schizophrenia OCD
Ke Xu, USA
1. Diagnosis
Joseph Zohar, Israel
13.00 – 14.30 | Room 201 A+B+C 2. Therapeutics
SYMPOSIUM 5 Naomi Fineberg, UK
Chair: Steven Potkin, USA
Partial dopamine agonists:
Wide spectrum medications for
psychiatric disorders
1. in vitro pharmacological profiles of
aripiprazole, brexpiprazole, and cariprazine
Pierre Blier, Canada
2. Clinical effects of aripiprazole in schizophrenia
Steven Potkin, USA
cinp2020.org | cinp2020@cinp.org 13Preliminary Programme Friday, 26 June 2020
14.45 – 16.15 | Plenary Hall 14.45 – 16.15 | Room 201 D+E+F
SYMPOSIUM 7 SYMPOSIUM 9
Chair: Hsien-Yuan Lane, Taiwan Chair: Kazutaka Ikeda, Japan
The Interplay of stress cascade Opioid Pharmacology Updates:
and NMDAR dysfunction in the Toward precision
pathogenesis of mental disorders: pharmacotherapy
Identifying novel antioxidants 1. Transcriptional regulation of opioid withdrawal
and NMDAR modulators for and microglia reactivity in humans and rodents
treatment and diagnosis Tuan Trang, Canada
1. Prevention of neurodevelopmental disorders 2. Involvement of adhesion molecules in
in offspring after maternal immune activation heroin- dependent patients in methadone
Kenji Hashimoto, Japan maintenance therapy
Yu-Li Liu, Taiwan
2. Oxidative stress and inflammation in
schizophrenia pathophysiology: add-on trial 3. Opioid receptor gene variation that
with N-acetyl-cysteine (NAC) in early psychosis moderates opioid pharmacotherapy
patients, towards biomarker guided treatment Henry Kranzler, USA
Kim Q. Do, Switzerland
4. Genetic mechanisms underlying individual
3. Identifying novel NMDAR modulators and differences in opioid sensitivity revealed by
antioxidants for the treatment of mental disorders genome-wide association studies
Hsien-Yuan Lane, Taiwan Kazutaka Ikeda, Japan
4. NMDAR- and antioxidants-related potential
biomarkers for mental disorders
Chieh-Hsin Lin, Taiwan 14:45 - 16:15 | Room 101 C+D
DEBATE
14.45 – 16.15 | Room 201 A+B+C Cannabinoids
Gabriella Gobbi vs. David Nutt
SYMPOSIUM 8
Chair: William E. Bunney, USA
Altered Circadian Rhythms in 14:45 - 16:15 | Room 102
Psychiatric Mood Disorders: CLINICAL FOCUS AND FRONTIERS
New Treatment Strategies ADHD
1. Strengthening of Circadian Rhythm Barbara Franke, The Netherlands
Amplitude Stabilizes and Improves Mood: Judith Rapoport, USA
Evidence from Animal Models
Colleen A. McClung, USA
2. Abnormal Core Clock Genes in MDD: Potential 16.15 – 16.45
Resetting with Rapid-Acting Antidepressants
William E. Bunney, USA
Networking Break
3. Adjustment of Central and Peripheral
Circadian Clocks in Humans
Diane B. Boivin, Canada
4. Light Signaling Alterations and Light Use in
Depression
Pierre A. Geoffroy, France
14 2020 CINP World CongressPreliminary Programme Friday, 26 June 2020
16.45 – 17.30 | Plenary Hall
PLENARY LECTURE
What is life: Implications for
brain health
Josef Penninger, Life Sciences Institute, UBC,
Canada
18.00 – 19.30
Top 10 Posters - Guided Session
cinp2020.org | cinp2020@cinp.org 15Preliminary Programme Saturday, 27 June 2020
08.45 - 09.30 | Plenary Hall 3. Role of neuroplasticity for treatment of
depression with antidepressants and
PLENARY LECTURE
psychotherapy
Big data analyses for Eero Castren, Finland
neuropsychopharmacology 4. Role of endocannabinoid signaling for the
Tung-Ping Su, Cheng-Hsin General Hospital, antidepressant activity of omega-3 fatty acids
Taiwan Kuan Pin Su, Taiwan
09.30 - 10:00 10:00 – 11.30 | Room 201 D+E+F
Networking Break SYMPOSIUM 12
Chair: Maurizio Popoli, Italy
10:00 – 11.30 | Plenary Hall Mechanisms of stress in
SYMPOSIUM 10
pathophysiology of brain illness
Chair: Karen Ersche, UK 1. Roles and mechanisms of
neuroinflammation in chronic stress-induced
Risk and Resilience in Addiction behavioral changes
1. Network failure predisposes individuals for Tomoyuki Furuyashiki, Japan
addiction 2. Microbiota-gut-brain (MGB) axis and
Karen Ersche, UK mental disorder
2. When drug meets vulnerability: how drugs Tallie Baram, USA
of abuse take advantage of pre-existing brain 3. Dynamic dissection of the stress response: a
abnormality matter of resilience or vulnerability
Karine Guillem, France Maurizio Popoli, Italy
3. Preclinical models of adolescent drug 4. How life experiences leave traces in
exposure and their consequences for later life descendants. Epigenetic mechanisms in
Shannon Gourley, USA the germline
4. The long-term consequences of adolescent Isabelle Mansuy, Switzerland
drug Use
Francesca Filbey, USA
11.30 – 13.00
Lunch
10:00 – 11.30 | Room 201 A+B+C
Satellite Symposia
SYMPOSIUM 11 Plenary Educational Workshop
Chair: Rainer Rupprecht, Germany Meet with...
Novel mechanisms of action of Naomi Fineberg: OCD*
antidepressant treatment Pierre Blier: TRD*
*Attendance limited. Pre-registration required;
1. Role of lipid rafts and G-protein signalling
preference given to CINP members
for antidepressant drug treatment
Mark Rasenick, USA
2. Role of glial cells and TSPO for
antidepressant and anxiolytic drug treatment
Rainer Rupprecht, Germany
16 2020 CINP World CongressPreliminary Programme Saturday, 27 June 2020
13.00 – 14.30 | Plenary Hall 13.00 – 14.30 | Room 201 D+E+F
SYMPOSIUM 13 SYMPOSIUM 15
Chair: Gerhard Gründer, Germany Chair: Katharina Domschke, Germany and Arturas
Petronis, Canada
Molecular imaging in drug
development: Is there any Epigenetics in Aging, Anxiety-
progress? and Stress-Related Disorders –
1. Molecular Imaging in Psychotropic Drug
Progress, Perspectives and Pitfalls
Development: Principles, Pitfalls and Promises 1. Circadian oscillations in epigenetics and
Gerhard Gründer, Germany their relevance to aging and mental disorders
Arturas Petronis, Canada
2. Imaging Methods to Optimize CNS Drug
Development 2. Epigenetics – the role of risk and resilience in
Eugenii A. (Ilan) Rabiner, UK PTSD
Divya Mehta, Australia
3. Molecular Imaging in the Development of
Novel Disease-Specific Therapeutics 3. Patho- and therapy-epigenetics of anxiety
for Dementia and affective disorders
Victor Villemagne, Australia Katharina Domschke, Germany
4. Neuroreceptor Imaging of Target 4. Histone acetylation as potential target for the
Engagement of New Antipsychotics in therapy of pathological fear and anxiety
Schizophrenia Nicolas Singewald, Austria
Dean F. Wong, USA
13:00 - 14:30 | Room 102
13.00 – 14.30 | Room 201 A+B+C CLINICAL FOCUS AND FRONTIERS
SYMPOSIUM 14 Depression
Chair: Sam Chamberlain, UK
1. Mechanisms
Impulsive-compulsive disorders: Elias Eriksson, Sweden
where neurobiology meets 2. Evidence
evidence-based treatment Carlos Zarate, USA
1. Introducing impulsivity-compulsivity: from
symptoms to prediction of latent
14.45 – 16.15 | Plenary Hall
trans-diagnostic phenotypes
Sam Chamberlain, UK SYMPOSIUM 16
2. Neurobiology of impulsive and compulsive Chair: Brian Dean, Australia
disorders: the ENIGMA variations The Importance of the Muscarinic
Dan Stein, South Africa
M1 Receptor in CNS Function
3: Problematic Use of the Internet (PUI): a new and as a Drug Target for Cognitive
mental disorder? Diagnostic and cognitive
considerations
Deficits and Sleep in Schizophrenia
Naomi Fineberg, UK 1. Evidence suggesting the muscarinic M1
receptor has a role in the aetiology and
4. New treatments for impulse control
treatment of schizophrenia
disorders and OCD identified using
Brian Dean, Australia
neurobiological models
Jon Grant, USA
cinp2020.org | cinp2020@cinp.org 17Preliminary Programme Saturday, 27 June 2020
2. The role of CHRM1 signalling in cognitive 2. Cytoskeleton regulators control synaptic
and behavioural symptoms of psychosis formation and function in neurodevelopmental
Geor Bakker, The Netherlands disorders
Yi-Ping Hsueh, Taiwan
3. Systems Biology of Mammalian Sleep/Wake
Cycles: The roles of muscarinic acetylcholine 3. Synaptic Dysfunction in Autism Models and
receptor in NREM and REM sleep Novel Treatment
Hiroki Ueda, Japan Zhen Yan, USA
4. Safety and Pharmacodynamic Effects of M1 4. Modelling Syndromic Autism Using Human
agonists in Humans Neurons and Mini-brains
Pradeep Nathan, UK Shawn Je, Singapore
14.45 – 16.15 | Room 201 A+B+C 14:45 - 16:15 | Room 101 C+D
SYMPOSIUM 17 DEBATE
Chair: Pierre Blier, Canada Pharmacogenetics
Rapid onset and sustained action Alessandro Serretti vs. Henk-Jan Guchelaar
of ketamine in depressive
episodes: from the laboratory
14:45 - 16:15 | Room 102
to the community
CLINICAL FOCUS AND FRONTIERS
1. Impact of ketamine on the intracellular
signaling beyond the N-methyl-D-aspartate Difficult to treat psychosis
receptors 1. Therapeutic approaches
Lisa Monteggia, USA Steven Potkin, USA
2. Neural networks involved in the action of 2. Pathophysiology and mechanisms of action
ketamine Anthony Grace, USA
Carlos Zarate, USA
3. Three-phase study of intravenous ketamine
Jennifer Phillips, Canada 16.15 – 16.45
4. Ketamine infusions Networking Break
Steve Levine, USA
16.45 – 17.30 | Plenary Hall
14.45 – 16.15 | Room 201 D+E+F PLENARY LECTURE
SYMPOSIUM 18 Brain mechanisms of insomnia:
Chair: Eunjoon Kim, South Korea fMRI and GWAS perspectives on
Synaptopathy mechanisms in causes and consequences
psychiatric disorders Eus Van Someren, Vrije Universiteit Amsterdam,
1. Synaptic and circuit dysfunctions in mouse The Netherlands
models of autism and neurodevelopmental
disorders
Eunjoon Kim, South Korea
18 2020 CINP World CongressPreliminary Programme Sunday, 28 June 2020
08.45 - 09.30 | Plenary Hall 1. Genome-wide DNA methylomic differences
between dorsolateral prefrontal and temporal
PLENARY LECTURE
pole cortices of bipolar disorder
Transgenerational epigenetics: A Marin Veldic, USA
key to understand
2. DNA repair gene promoter methylation in
neurodevelopmental diseases postmortem gray matter of patients with
Noriko Osumi, Tohoku University, Japan bipolar disorder
Aysegul Ozerdem, Turkey
09.30 - 10:00 3. Single-cell transcriptomics reveals cell
population specific pathologies in bipolar
Networking Break disorder
W. Brad Ruzicka, USA
10:00 – 11.30 | Plenary Hall 4. Membrane protein clustering in peripheral
lymphocytes as a putative biomarker of mood
SYMPOSIUM 19 and psychotic disorders
Chair: Mark Weiser, IIsrael Hector Caruncho, Canada
Estrogen and psychiatric illnesses
1. Aromatase in the brain and human personality 10:00 – 11.30 | Room 201 D+E+F
Kayo Takahashi, Japan
SYMPOSIUM 21
2. Circuit and Cellular Substrates of the
Chair: David Nutt, UK and Rupert Lanzenberger, Austria
Differential Behavioral Response to Ovarian
Steroids in Women with Reproductive Stronger together? Using PET
Endocrine-related Mood Disorders and MRI in
Peter Schmidt, USA neuropsychopharmacology
3. Prenatal steroid hormones and autistic traits 1. 5-HT2A receptor PET, serotonin release and
in expectant mothers and their children amygdala fMRI responses in depression
Alexandros Tsompanidis, UK David Nutt, UK
4. Effect of adjunctive estradiol on 2. 5-HT reuptake site and 5-HT1A receptor
schizophrenia among women of childbearing imaging and emotions
age: A randomized controlled trial Rupert Lanzenberger, Austria
Mark Weiser, Israel
3. Mu-opioid receptor availability and
functional connectivity during reward
10:00 – 11.30 | Room 201 A+B+C processing in gambling disorder
Chen-Chia Lan, Taiwan
SYMPOSIUM 20
Chair: W. Brad Ruzicka, USA
4. Dopamine D2 receptors: simultaneous PET
measures and fMRI signals
Epigenomic pathophysiology of Bruce Rosen, USA
Bipolar Disorder: Human
tissue investigations of
mechanisms, biomarkers, and
single-cell pathology
cinp2020.org | cinp2020@cinp.org 19Preliminary Programme Sunday, 28 June 2020
10:00 - 11:30 | Room 102 13.00 – 14.30 | Room 201 A+B+C
CLINICAL FOCUS AND FRONTIERS SYMPOSIUM 23
Insomnia Chair: Gustavo Turecki, Canada
Eus van Someren, The Netherlands Mechanisms of stress response
Diane Boivin, Canada at the single cell resolution
1. The neuroendocrine stress response at a
single cell resolution
11.30 – 13.00
Alon Chen, Israel
Lunch 2. Single-cell transcriptomic changes in the
Satellite Symposia hippocampus of non-human primates
Plenary Educational Workshop as a function of stress and treatment response
Meet with... Michael Meaney, Singapore
Gabriella Gobbi: Cannabis* 3. Using brain organoids to model stress at the
Elias Eriksson: Antidepressants* single cell resolution
*Attendance limited. Pre-registration required; Elisabeth Binder, Germany
preference given to CINP members
4. LCM-Seq: single cell-type transcriptomic
profiling of the prefrontal cortex as a
function of childhood abuse
13.00 – 14.30 | Plenary Hall
Gustavo Turecki, Canada
SYMPOSIUM 22
Chair: Eileen Lueders, New Zealand
13.00 – 14.30 | Room 201 D+E+F
Transgender hormone therapy:
SYMPOSIUM 24
effects on brain structure and
Chair: Kenji Hashimoto, Japan
function
Novel Molecular and Cellular
1. Hormonal treatment effects on the brain:
findings from the Enigma transgender
Mechanisms of Rapid-acting
persons working group Antidepressant Ketamine and
Sven C. Müller, Belgium Its Enantiomers
2. Sex matters – a multivariate pattern analysis 1. Molecular mechanisms underlying
of sex and gender rapid-acting and long-lasting antidepressant
Pia Baldinger-Melich, Austria effects of ketamine
Kenji Hashimoto, Japan
3. Effects of sex hormones on serotonergic
neurotransmission 2. Role of immune system in rapid-acting and
Georg S. Kranz, Hong Kong long-lasting antidepressant effects of ketamine
Kai Zhang, China
4. A new theory about the neurobiology of
3. Rapamycin, an immunosuppressant and
gender dysphoria
mTORC1 inhibitor, triples the antidepressant
Sarah M. Burke, The Netherlands response rate of ketamine at 2 weeks following
treatment: A double-blind, placebo-controlled,
cross-over, randomized clinical trial.
Chadi G. Abdallah, USA
4. New clinical developments for
treatment-resistant depression and suicidality
Sanjay J. Mathew, USA
20 2020 CINP World CongressPreliminary Programme Sunday, 28 June 2020
13:00 - 14:30 | Room 101 A+B
DEBATE
Is long-term treatment with
antipsychotics justified?
Konstantinos Fountoulakis vs. Robin Murray
14.45 – 15.30 | Plenary Hall
PLENARY LECTURE
Effects of cannabis in adolescence
and depression risk in young
adulthood: From animals to
human studies
Gabriella Gobbi, McGill University, Canada
15.45 – 16.15 | Plenary Hall
Closing Ceremony
cinp2020.org | cinp2020@cinp.org 21Plenary Speakers
Friday 26 June 2020 Friday 26 June 2020
08:45 – 09:30 16:45 – 17:30
From genes to clinical pheno- What is life: Implications for
type in ADHD across the lifespan brain health
Barbara Franke, Josef Penninger,
Radboud University, The Netherlands Life Sciences Institute, UBC, Canada
Barbara Franke, PhD is professor of Molecular Josef Penninger, MD was formerly a lead
Psychiatry at Radboud University in Nijmegen, researcher at the Amgen Research Institute in
The Netherlands, where she is based at the Toronto. Since 2002 he was the founding and
Human Genetics and Psychiatry departments of scientific director of the newly established
the Radboud UMC. Her research is focused on Institute of Molecular Biotechnology in Austria.
understanding the genetic contribution to 2018 he accepted the appointment as Director of
neurodevelopmental psychiatric disorders, the Life Sciences Institute at the University of
especially ADHD and its comorbidities. British Columbia in Canada.
22 2020 CINP World CongressPlenary Speakers
Saturday 27 June 2020 Saturday 27 June 2020
08:45 – 09:30 16:45 – 17:30
Big data analyses for neuropsy- Brain mechanisms of insomnia:
chopharmacology fMRI and GWAS perspectives
on causes and consequences
Tung-Ping Su,
Cheng-Hsin General Hospital, Taiwan Eus Van Someren,
Vrije Universiteit Amsterdam, The Netherlands
Professor Tung-Ping Su is the chair of the
Department of Psychiatry, Cheng-Hsin General Prof. Eus Van Someren was trained in physics,
Hospital and Professor Emeritus of National psychophysiology and neuropsychology and
Yang-Ming University, Taipei, Taiwan. Dr. Su was received a cum laude PhD in neurobiology from
the previous president of AsCNP. His interests are the faculty of medicine. He leads a team at the
studying mood disorders and brain imaging. Dr. Netherlands Institute for Neuroscience, aiming to
Su is one of the pioneers conducting clinical trials unravel brain mechanisms of chronic insomnia.
on ketamine and depression in the Asian He received prestigious grants including VIDI,
populations and is the recipient of the “Academic VICI and ERC-AdG, and founded the Sleep
Achievement Award” from the Taiwanese Society Registry (sleepregistry.org) for rich phenotyping
of Psychiatry. of over 10,000 volunteers. He (co)-authored on
more than 250 peer-reviewed publications in
scientific journals including NJEM, Jama, Nature
Genetics, Nature Neuroscience, Lancet
Psychiatry, Archives of General Psychiatry,
Psychological Bulletin, Brain and PNAS and is
widely cited (H-index 53). His informal
infectious enthusiasm for a neuroscience of
insomnia make him a frequently invited speaker,
e.g. at TED-X.
cinp2020.org | cinp2020@cinp.org 23Plenary Speakers
Sunday 28 June 2020 Sunday 28 June 2020
08:45 – 09:30 16:45 – 17:30
Transgenerational epigenetics: Effects of cannabis in adolescence
A key to understand neurode- and depression risk in young
velopmental diseases adulthood: From animals to
human studies
Noriko Osumi,
Tohoku University, Japan Gabriella Gobbi,
McGill University, Canada
Prof. Osumi has graduated Tokyo Medical and
Dental University, been given PhD thesis from Dr. Gabriella Gobbi is a Professor in the Department
the same university, and now is a professor of of Psychiatry, McGill University.
Tohoku University School of Medicine since She leads a laboratory of basic science (Neurobiolog-
1998. She is appointed in various governmental ical Psychiatry Unit) and works as a Staff Psychiatrist
committees such as ethical issues, grant system at the Mood Disorder Clinic of the McGill
development, and career paths for young University Health Center. Her research approach
scientists, and also chosen as a youngest member spans from bench to bedside, bridging the gaps
of Japanese Council Japan since 2005. Her between fundamental and clinical research. Dr.
research interest covers broad areas such as pre- Gobbi received her MD (1991) and her specialty in
and postnatal development of the brain and Psychiatry and Psychotherapy (1995) from the
craniofacial region, and behavior of animals as Catholic University of Rome (Italy). She also earned
models of psychiatric diseases. More specifically, a PhD in Neuroscience at the University of Cagliari,
she is recently eager to understand regulatory Italy) and finalized a post-doc at McGill University
mechanisms of neurogenesis and maintenance of (Montreal, Canada) in 1998. Dr Gobbi’s lab is
neural stem cells at cellular and molecular levels interested in understanding the pathophysiology of
both in embryonic and postnatal stages. major depression and sleep related disorders and in
Manipulating embryos and imaging brain cells the discovery of new treatments and cures for them.
are expertise of her lab. In particular, her laboratory is studying the short-
and long-term effects of cannabis use in mood and
anxiety, and the potential beneficial effects of the
drugs acting on the endocannabinoid system
(endogenous cannabis) in the cure of mental
diseases. Her lab is also studying the effect of
melatonin in mood, anxiety and sleep regulation in
an effort to understand how novel selective ligands
for melatonin receptors (called MT1 and MT2
receptors) can be used to treat seasonal depression,
major depression, sleep disorders, as well as pain.
24 2020 CINP World CongressCINP Head Office
Nußdorfer Straße 20/24
1090 Vienna
Austria
Phone: +43 1 3532024
Fax: +1 604 681 1049
info@cinp.org
www.cinp.org
For further information on CINP and to keep up to date with all CINP activities
please visit www.cinp.orgYou can also read
